PURPOSE: To assess the incidence, predisposing factors, and clinical characteristics of insufficiency fractures (IF) in patients with prostate cancer, who received pelvic radiotherapy as part of their definitive treatment. METHODS AND MATERIALS: The charts of 134 prostate cancer patients, who were treated with pelvic radiotherapy between 1998 and 2007 were retrospectively reviewed. IF was diagnosed by bone scan and/or CT and/or MRI. The cumulative incidence of symptomatic IF was estimated by actuarial methods. RESULTS: Eight patients were identified with symptomatic IF after a median follow-up period of 68 months (range, 12-116 months). The 5-year cumulative incidence of symptomatic IF was 6.8%. All patients presented with lower back pain. Insufficiency fracture developed at a median time of 20 months after the end of radiotherapy and was managed conservatively without any need for hospitalization. Three patients were thought to have metastatic disease because of increased uptake in their bone scans. However, subsequent CT and MR imaging revealed characteristic changes of IF, avoiding any further intervention. No predisposing factors for development of IF could be identified. CONCLUSIONS: Pelvic IF is a rare complication of pelvic radiotherapy in prostate cancer. Knowledge of pelvic IF is essential to rule out metastatic disease and prevent unnecessary treatment, especially in a patient cohort with high-risk features for distant spread. (c) 2010 Elsevier Inc. All rights reserved.
PURPOSE: To assess the incidence, predisposing factors, and clinical characteristics of insufficiency fractures (IF) in patients with prostate cancer, who received pelvic radiotherapy as part of their definitive treatment. METHODS AND MATERIALS: The charts of 134 prostate cancerpatients, who were treated with pelvic radiotherapy between 1998 and 2007 were retrospectively reviewed. IF was diagnosed by bone scan and/or CT and/or MRI. The cumulative incidence of symptomatic IF was estimated by actuarial methods. RESULTS: Eight patients were identified with symptomatic IF after a median follow-up period of 68 months (range, 12-116 months). The 5-year cumulative incidence of symptomatic IF was 6.8%. All patients presented with lower back pain. Insufficiency fracture developed at a median time of 20 months after the end of radiotherapy and was managed conservatively without any need for hospitalization. Three patients were thought to have metastatic disease because of increased uptake in their bone scans. However, subsequent CT and MR imaging revealed characteristic changes of IF, avoiding any further intervention. No predisposing factors for development of IF could be identified. CONCLUSIONS: Pelvic IF is a rare complication of pelvic radiotherapy in prostate cancer. Knowledge of pelvic IF is essential to rule out metastatic disease and prevent unnecessary treatment, especially in a patient cohort with high-risk features for distant spread. (c) 2010 Elsevier Inc. All rights reserved.
Authors: V Nardone; P Tini; S F Carbone; A Grassi; M Biondi; L Sebaste; T Carfagno; E Vanzi; G De Otto; G Battaglia; G Rubino; P Pastina; G Belmonte; L N Mazzoni; F Banci Buonamici; M A Mazzei; L Pirtoli Journal: Osteoporos Int Date: 2017-02-27 Impact factor: 4.507
Authors: David C Moore; Kirk A Keegan; Matthew J Resnick; Rosana Eisenberg; Ginger E Holt; Michael S Cookson Journal: Urology Date: 2013-02 Impact factor: 2.649
Authors: R Rizzoli; J-J Body; M-L Brandi; J Cannata-Andia; D Chappard; A El Maghraoui; C C Glüer; D Kendler; N Napoli; A Papaioannou; D D Pierroz; M Rahme; C H Van Poznak; T J de Villiers; G El Hajj Fuleihan Journal: Osteoporos Int Date: 2013-10-22 Impact factor: 4.507
Authors: Laura E Wright; Jeroen T Buijs; Hun-Soo Kim; Laura E Coats; Anne M Scheidler; Sutha K John; Yun She; Sreemala Murthy; Ning Ma; Helen J Chin-Sinex; Teresita M Bellido; Ted A Bateman; Marc S Mendonca; Khalid S Mohammad; Theresa A Guise Journal: J Bone Miner Res Date: 2015-06-08 Impact factor: 6.741
Authors: Lucas K Vitzthum; Helen Park; Kaveh Zakeri; Elena S Heide; Vinit Nalawade; Arno J Mundt; Florin Vaida; James D Murphy; Loren K Mell Journal: Int J Radiat Oncol Biol Phys Date: 2019-10-11 Impact factor: 7.038
Authors: Valerio Nardone; Paolo Tini; Stefania Croci; Salvatore Francesco Carbone; Lucio Sebaste; Tommaso Carfagno; Giuseppe Battaglia; Pierpaolo Pastina; Giovanni Rubino; Maria Antonietta Mazzei; Luigi Pirtoli Journal: Quant Imaging Med Surg Date: 2018-02